Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Genetically distinct within-host subpopulations of hepatitis C virus persist after Direct-Acting Antiviral treatment failure.

Zhao L. et al, (2025), PLoS Pathog, 21

Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.

Mellors J. et al, (2025), Nat Commun, 16

Whole genome sequencing of hepatitis B virus using tiled amplicon (HEPTILE) and probe based enrichment on Illumina and Nanopore platforms.

Lumley SF. et al, (2025), Sci Rep, 15

Reply to: "Understanding virologic heterogeneity in chronic hepatitis B treatment".

Matthews PC. et al, (2025), JHEP Rep, 7

Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.

Varley M. et al, (2025), BMJ Open, 15

Distinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy

Wang T. et al, (2025), JHEP Reports, 7

The Differential Complement, Fc and Chemokine Receptor Expression of B Cells in IgG4-Related Pancreatobiliary Disease and Primary Sclerosing Cholangitis and Its Relevance for Targeting B Cell Pathways in Disease.

Cargill T. et al, (2024), Biomedicines, 12

Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study

Perez-Campuzano V. et al, (2024), JHEP Reports, 6

Distinct Requirements for CD4+ T Cell Help for Immune Responses Induced by mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines.

Yong L. et al, (2024), Eur J Immunol

Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.

Colton H. et al, (2024), Br J Haematol

Prospective cohort for early detection of liver cancer (Pearl): a study protocol.

Khanna K. et al, (2024), BMJ Open, 14

Corrigendum to ‘Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study’ [The Lancet Regional Health – Europe 35 (2023) 100747] (The Lancet Regional Health - Europe (2023) 35, (S2666776223001667), (10.1016/j.lanepe.2023.100747))

Evans RA. et al, (2024), The Lancet Regional Health - Europe, 44

Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom.

Garay OU. et al, (2024), Value Health

Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.

Lim YJ. et al, (2024), Br J Haematol, 205, 440 - 451

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV.

Davis C. et al, (2024), Vaccines (Basel), 12

The lipidome in phenotyping hepatitis B infection (‘LiPHe-B’): preliminary results from our pilot study

Delphin M. et al, (2024), Journal of Hepatology, 80, S750 - S750

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Goodyear CS. et al, (2024), Lancet Rheumatol

Plasmacytoid dendritic cells are central regulators of the humoral ChAdOx1 nCoV-19 vaccine response in a human tonsil organoid model

Provine N. et al, (2024), Journal of Immunology, 212, 0089_4613 - 0089_4613

Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial.

Hirschfield GM. et al, (2024), Hepatol Commun, 8

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.

Jackson S. et al, (2024), Lancet Microbe

Load More

1
2
3
4
5
6
7
...
»